Last reviewed · How we verify
INDIUM IN 111 SATUMOMAB PENDETIDE — Competitive Intelligence Brief
marketed
Monoclonal antibody
Live · refreshed every 30 min
Target snapshot
INDIUM IN 111 SATUMOMAB PENDETIDE (INDIUM IN 111 SATUMOMAB PENDETIDE).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| INDIUM IN 111 SATUMOMAB PENDETIDE TARGET | INDIUM IN 111 SATUMOMAB PENDETIDE | marketed | 1991-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- INDIUM IN 111 SATUMOMAB PENDETIDE CI watch — RSS
- INDIUM IN 111 SATUMOMAB PENDETIDE CI watch — Atom
- INDIUM IN 111 SATUMOMAB PENDETIDE CI watch — JSON
- INDIUM IN 111 SATUMOMAB PENDETIDE alone — RSS
Cite this brief
Drug Landscape (2026). INDIUM IN 111 SATUMOMAB PENDETIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/indium-in-111-satumomab-pendetide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab